Last 12 months
Inside the activity.
0 purchase rows · 240 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 200 |
| Dec 2025 | 0 | 3 |
| Jan 2026 | 0 | 31 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 2 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 3 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 01, 2018 Filed May 3, 2018 20:26 UTC |
Conterno Enrique ASVP&Pres, LillyDiab & LillyUSA
|
Exercise / conversionCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-18-000138 · wf-form4_152537915780405.xml · nonDerivative · entry 1 Conterno Enrique A · CIK 0001476151 · SVP&Pres, LillyDiab & LillyUSA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,468 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2018 Filed May 3, 2018 20:29 UTC |
Shaw ChristiSVP and Pres., Lilly Bio-Meds
|
Exercise / conversionRestricted Stock Unit · Derivative | 13,750 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-18-000140 · wf-form4_152537932835597.xml · derivative · entry 3 Shaw Christi · CIK 0001702473 · SVP and Pres., Lilly Bio-Meds 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,750 Underlying: Common Stock · 13,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. F2 · derivative.exercise_date: The restricted stock units vest in two equal installments on May 1, 2018 and May 1, 2019. F2 · derivative.expiration_date: The restricted stock units vest in two equal installments on May 1, 2018 and May 1, 2019. Read SEC document |
| May 01, 2018 Filed May 3, 2018 20:29 UTC |
Shaw ChristiSVP and Pres., Lilly Bio-Meds
|
Tax withholdingCommon Stock | 5,324 | $81.07 | $431,616.68 |
DisclosureSEC source: 0000059478-18-000140 · wf-form4_152537932835597.xml · nonDerivative · entry 2 Shaw Christi · CIK 0001702473 · SVP and Pres., Lilly Bio-Meds 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,426 Read SEC document |
| May 01, 2018 Filed May 3, 2018 20:29 UTC |
Shaw ChristiSVP and Pres., Lilly Bio-Meds
|
Exercise / conversionCommon Stock | 13,750 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-18-000140 · wf-form4_152537932835597.xml · nonDerivative · entry 1 Shaw Christi · CIK 0001702473 · SVP and Pres., Lilly Bio-Meds 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2018 Filed May 3, 2018 20:34 UTC |
Simmons Jeffrey NSVP&Pres. Elanco Animal Health
|
Exercise / conversionRestricted Stock Unit · Derivative | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-18-000142 · wf-form4_152537963067006.xml · derivative · entry 5 Simmons Jeffrey N · CIK 0001479079 · SVP&Pres. Elanco Animal Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2018-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| May 01, 2018 Filed May 3, 2018 20:34 UTC |
Simmons Jeffrey NSVP&Pres. Elanco Animal Health
|
Tax withholdingCommon Stock | 8,716 | $81.07 | $706,606.12 |
DisclosureSEC source: 0000059478-18-000142 · wf-form4_152537963067006.xml · nonDerivative · entry 2 Simmons Jeffrey N · CIK 0001479079 · SVP&Pres. Elanco Animal Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,485 Read SEC document |
| May 01, 2018 Filed May 3, 2018 20:34 UTC |
Simmons Jeffrey NSVP&Pres. Elanco Animal Health
|
Exercise / conversionCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-18-000142 · wf-form4_152537963067006.xml · nonDerivative · entry 1 Simmons Jeffrey N · CIK 0001479079 · SVP&Pres. Elanco Animal Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,201 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 25, 2018 Filed Apr 26, 2018 16:38 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 1,100 | $81.57 | $89,728.10 |
DisclosureSEC source: 0001209191-18-026160 · doc4.xml · nonDerivative · entry 2 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,895,804 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.50 to $81.62, inclusive. Read SEC document |
| April 25, 2018 Filed Apr 26, 2018 16:38 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 178,900 | $80.85 | $14,463,886.10 |
DisclosureSEC source: 0001209191-18-026160 · doc4.xml · nonDerivative · entry 1 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,896,904 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.50 to $81.49, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4. Read SEC document |
| April 16, 2018 Filed Apr 17, 2018 19:29 UTC |
Mahony SusanSVP & Pres., Lilly Oncology
|
SaleCommon Stock | 17,379 | $80.08 | $1,391,710.32 |
DisclosureSEC source: 0000059478-18-000123 · wf-form4_152399337145959.xml · nonDerivative · entry 2 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,273 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 22, 2018. F3 · price: This transaction was executed in multiple trades at prices ranging from $80.00 to $80.27. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 16, 2018 Filed Apr 18, 2018 13:51 UTC |
Alvarez RalphDirector
|
GrantCommon Stock | 136 | $80.12 | $10,896.32 |
DisclosureSEC source: 0000059478-18-000125 · wf-form4_152405944503575.xml · nonDerivative · entry 1 Alvarez Ralph · CIK 0001310215 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,322 Read SEC document |
| April 16, 2018 Filed Apr 18, 2018 13:54 UTC |
Fyrwald J ErikDirector
|
GrantCommon Stock | 68 | $80.12 | $5,448.16 |
DisclosureSEC source: 0000059478-18-000127 · wf-form4_152405963264751.xml · nonDerivative · entry 1 Fyrwald J Erik · CIK 0001343564 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,776 Read SEC document |
| April 16, 2018 Filed Apr 18, 2018 13:57 UTC |
LUCIANO JUAN RDirector
|
GrantCommon Stock | 121 | $80.12 | $9,694.52 |
DisclosureSEC source: 0000059478-18-000129 · wf-form4_152405979708318.xml · nonDerivative · entry 1 LUCIANO JUAN R · CIK 0001455792 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,835 Read SEC document |
| April 16, 2018 Filed Feb 1, 2019 19:38 UTC Amendment |
Mahony SusanSVP & Pres., Lilly Oncology
|
SaleCommon Stock | 17,379 | $80.08 | $1,391,710.32 |
DisclosureSEC source: 0000059478-19-000022 · wf-form4a_154904987716452.xml · nonDerivative · entry 1 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,685 F1 · balance_after: This amendment is being filed to correct the total holdings held by the reporting person following the transaction reported on the original Form 4 filed on April 17, 2018. Read SEC document |
| April 13, 2018 Filed Apr 17, 2018 19:29 UTC |
Mahony SusanSVP & Pres., Lilly Oncology
|
SaleCommon Stock | 5,165 | $80.14 | $413,923.10 |
DisclosureSEC source: 0000059478-18-000123 · wf-form4_152399337145959.xml · nonDerivative · entry 1 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,652 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 22, 2018. F2 · price: This transaction was executed in multiple trades at prices ranging from $80.00 to $80.41. The price reported reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 19, 2018 Filed Mar 21, 2018 17:02 UTC |
Alvarez RalphDirector
|
GrantCommon Stock | 139 | $78.57 | $10,921.23 |
DisclosureSEC source: 0000059478-18-000117 · wf-form4_152165174107261.xml · nonDerivative · entry 1 Alvarez Ralph · CIK 0001310215 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,186 Read SEC document |
| March 19, 2018 Filed Mar 21, 2018 17:08 UTC |
Fyrwald J ErikDirector
|
GrantCommon Stock | 69 | $78.57 | $5,421.33 |
DisclosureSEC source: 0000059478-18-000119 · wf-form4_152165212020781.xml · nonDerivative · entry 1 Fyrwald J Erik · CIK 0001343564 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,708 Read SEC document |
| March 19, 2018 Filed Mar 21, 2018 17:12 UTC |
LUCIANO JUAN RDirector
|
GrantCommon Stock | 123 | $78.57 | $9,664.11 |
DisclosureSEC source: 0000059478-18-000121 · wf-form4_152165232410775.xml · nonDerivative · entry 1 LUCIANO JUAN R · CIK 0001455792 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,714 Read SEC document |
| March 16, 2018 Filed Mar 20, 2018 16:06 UTC |
Smiley Joshua LSVP and CFO
|
SaleCommon Stock | 3,000 | $79.20 | $237,600.00 |
DisclosureSEC source: 0000059478-18-000115 · wf-form4_152156199292929.xml · nonDerivative · entry 1 Smiley Joshua L · CIK 0001725189 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,029 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2018. Read SEC document |
| March 13, 2018 Filed Feb 1, 2019 19:09 UTC |
Simmons Jeffrey NSVP&Pres. Elanco Animal Health
|
GiftCommon Stock | 3,200 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-19-000020 · wf-form5_154904812376432.xml · nonDerivative · entry 1 Simmons Jeffrey N · CIK 0001479079 · SVP&Pres. Elanco Animal Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,258 Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 20:30 UTC |
Zakrowski Donald AChief Accounting Officer
|
SaleCommon Stock | 860 | $76.50 | $65,790.00 |
DisclosureSEC source: 0000059478-18-000105 · wf-form4_152028183233987.xml · nonDerivative · entry 1 Zakrowski Donald A · CIK 0001561539 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Indirect · 401(k) Disclosed balance after: 1,637 Read SEC document |
| February 21, 2018 Filed Feb 23, 2018 22:42 UTC |
Zakrowski Donald AChief Accounting Officer
|
SaleCommon Stock | 876 | $77.55 | $67,933.80 |
DisclosureSEC source: 0000059478-18-000103 · wf-form4_151942570989986.xml · nonDerivative · entry 1 Zakrowski Donald A · CIK 0001561539 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Indirect · 401(k) Disclosed balance after: 2,472 Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 22:12 UTC |
Alvarez RalphDirector
|
GrantCommon Stock | 141 | $77.55 | $10,934.55 |
DisclosureSEC source: 0000059478-18-000094 · wf-form4_151933751772555.xml · nonDerivative · entry 1 Alvarez Ralph · CIK 0001310215 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,768 Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 22:15 UTC |
Fyrwald J ErikDirector
|
GrantCommon Stock | 70 | $77.55 | $5,428.50 |
DisclosureSEC source: 0000059478-18-000096 · wf-form4_151933770540908.xml · nonDerivative · entry 1 Fyrwald J Erik · CIK 0001343564 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,229 Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 22:17 UTC |
LUCIANO JUAN RDirector
|
GrantCommon Stock | 125 | $77.55 | $9,693.75 |
DisclosureSEC source: 0000059478-18-000098 · wf-form4_151933782402531.xml · nonDerivative · entry 1 LUCIANO JUAN R · CIK 0001455792 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,553 Read SEC document |
| February 16, 2018 Filed Feb 21, 2018 15:28 UTC |
Norton JohnaSenior VP, Global Quality
|
Exercise / conversionRestricted Stock Unit · Derivative | 48 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-18-000091 · wf-form4_151922689429729.xml · derivative · entry 6 Norton Johna · CIK 0001702471 · Senior VP, Global Quality 10b5-1 filing: Not disclosed Ownership: Indirect · by partner Disclosed balance after: 145 Underlying: Common Stock · 48 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. F2 · derivative.exercise_date: The Restricted Stock Units vest in three installments, 48 on February 16, 2018; 48 on February 16, 2019; and 97 on February 16, 2020. F2 · derivative.expiration_date: The Restricted Stock Units vest in three installments, 48 on February 16, 2018; 48 on February 16, 2019; and 97 on February 16, 2020. Read SEC document |
| February 16, 2018 Filed Feb 21, 2018 15:28 UTC |
Norton JohnaSenior VP, Global Quality
|
Tax withholdingCommon Stock | 14 | $78.02 | $1,092.28 |
DisclosureSEC source: 0000059478-18-000091 · wf-form4_151922689429729.xml · nonDerivative · entry 2 Norton Johna · CIK 0001702471 · Senior VP, Global Quality 10b5-1 filing: Not disclosed Ownership: Indirect · by partner Disclosed balance after: 34 Read SEC document |
| February 16, 2018 Filed Feb 21, 2018 15:28 UTC |
Norton JohnaSenior VP, Global Quality
|
Exercise / conversionCommon Stock | 48 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-18-000091 · wf-form4_151922689429729.xml · nonDerivative · entry 1 Norton Johna · CIK 0001702471 · Senior VP, Global Quality 10b5-1 filing: Not disclosed Ownership: Indirect · by partner Disclosed balance after: 48 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 09, 2018 Filed Feb 13, 2018 15:47 UTC |
Lundberg Jan MEVP,Science&Tech and Pres. LRL
|
GrantRestricted Stock Unit · Derivative | 7,871 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-18-000080 · wf-form4_151853685912764.xml · derivative · entry 3 Lundberg Jan M · CIK 0001480120 · EVP,Science&Tech and Pres. LRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,871 Underlying: Common Stock · 7,871 shares Expires 2021-02-09 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 05, 2018 Filed Feb 5, 2018 23:37 UTC |
Simmons Jeffrey NSVP&Pres. Elanco Animal Health
|
SaleCommon Stock | 9,625 | $81.12 | $780,780.00 |
DisclosureSEC source: 0000059478-18-000076 · wf-form4_151787382601710.xml · nonDerivative · entry 3 Simmons Jeffrey N · CIK 0001479079 · SVP&Pres. Elanco Animal Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,201 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 9, 2017. F2 · price: This transaction was executed in multiple trades at prices ranging from $80.80 to $81.43. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 05, 2018 Filed Feb 5, 2018 23:39 UTC |
Zakrowski Donald AChief Accounting Officer
|
SaleCommon Stock | 900 | $81.09 | $72,981.00 |
DisclosureSEC source: 0000059478-18-000078 · wf-form4_151787395689915.xml · nonDerivative · entry 1 Zakrowski Donald A · CIK 0001561539 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,130 Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 23:09 UTC |
Barnes Melissa SChief Eth/Cmpl Ofcr & SVP, ERM
|
Exercise / conversionRestricted Stock Unit · Derivative | 6,398 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-18-000058 · wf-form4_151787218358969.xml · derivative · entry 4 Barnes Melissa S · CIK 0001566364 · Chief Eth/Cmpl Ofcr & SVP, ERM 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,398 shares Expires 2018-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 23:09 UTC |
Barnes Melissa SChief Eth/Cmpl Ofcr & SVP, ERM
|
Tax withholdingCommon Stock | 2,789 | $81.45 | $227,164.05 |
DisclosureSEC source: 0000059478-18-000058 · wf-form4_151787218358969.xml · nonDerivative · entry 2 Barnes Melissa S · CIK 0001566364 · Chief Eth/Cmpl Ofcr & SVP, ERM 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,318 Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 23:09 UTC |
Barnes Melissa SChief Eth/Cmpl Ofcr & SVP, ERM
|
Exercise / conversionCommon Stock | 6,398 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-18-000058 · wf-form4_151787218358969.xml · nonDerivative · entry 1 Barnes Melissa S · CIK 0001566364 · Chief Eth/Cmpl Ofcr & SVP, ERM 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,107 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 23:12 UTC |
Conterno Enrique ASVP&Pres, LillyDiab & LillyUSA
|
Exercise / conversionRestricted Stock Unit · Derivative | 21,326 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-18-000060 · wf-form4_151787233130801.xml · derivative · entry 4 Conterno Enrique A · CIK 0001476151 · SVP&Pres, LillyDiab & LillyUSA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,326 shares Expires 2018-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 23:12 UTC |
Conterno Enrique ASVP&Pres, LillyDiab & LillyUSA
|
Tax withholdingCommon Stock | 9,512 | $81.45 | $774,752.40 |
DisclosureSEC source: 0000059478-18-000060 · wf-form4_151787233130801.xml · nonDerivative · entry 2 Conterno Enrique A · CIK 0001476151 · SVP&Pres, LillyDiab & LillyUSA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,468 Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 23:12 UTC |
Conterno Enrique ASVP&Pres, LillyDiab & LillyUSA
|
Exercise / conversionCommon Stock | 21,326 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-18-000060 · wf-form4_151787233130801.xml · nonDerivative · entry 1 Conterno Enrique A · CIK 0001476151 · SVP&Pres, LillyDiab & LillyUSA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,980 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 23:15 UTC |
Fry Stephen FSVP, HR & Diversity
|
Exercise / conversionRestricted Stock Unit · Derivative | 17,060 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-18-000062 · wf-form4_151787249497944.xml · derivative · entry 4 Fry Stephen F · CIK 0001513324 · SVP, HR & Diversity 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,060 shares Expires 2018-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 23:15 UTC |
Fry Stephen FSVP, HR & Diversity
|
Tax withholdingCommon Stock | 7,609 | $81.45 | $619,753.05 |
DisclosureSEC source: 0000059478-18-000062 · wf-form4_151787249497944.xml · nonDerivative · entry 2 Fry Stephen F · CIK 0001513324 · SVP, HR & Diversity 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,211 Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 23:15 UTC |
Fry Stephen FSVP, HR & Diversity
|
Exercise / conversionCommon Stock | 17,060 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-18-000062 · wf-form4_151787249497944.xml · nonDerivative · entry 1 Fry Stephen F · CIK 0001513324 · SVP, HR & Diversity 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,820 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 23:19 UTC |
Harrington Michael JSenior VP and General Counsel
|
Exercise / conversionRestricted Stock Unit · Derivative | 24,524 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-18-000064 · wf-form4_151787272781244.xml · derivative · entry 4 Harrington Michael J · CIK 0001566340 · Senior VP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 24,524 shares Expires 2018-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 23:19 UTC |
Harrington Michael JSenior VP and General Counsel
|
Tax withholdingCommon Stock | 10,811 | $81.45 | $880,555.95 |
DisclosureSEC source: 0000059478-18-000064 · wf-form4_151787272781244.xml · nonDerivative · entry 2 Harrington Michael J · CIK 0001566340 · Senior VP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,927 Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 23:19 UTC |
Harrington Michael JSenior VP and General Counsel
|
Exercise / conversionCommon Stock | 24,524 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-18-000064 · wf-form4_151787272781244.xml · nonDerivative · entry 1 Harrington Michael J · CIK 0001566340 · Senior VP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,738 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 23:21 UTC |
Lundberg Jan MEVP,Science&Tech and Pres. LRL
|
Exercise / conversionRestricted Stock Unit · Derivative | 36,252 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-18-000066 · wf-form4_151787287602417.xml · derivative · entry 4 Lundberg Jan M · CIK 0001480120 · EVP,Science&Tech and Pres. LRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 36,252 shares Expires 2018-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 23:21 UTC |
Lundberg Jan MEVP,Science&Tech and Pres. LRL
|
Tax withholdingCommon Stock | 16,169 | $81.45 | $1,316,965.05 |
DisclosureSEC source: 0000059478-18-000066 · wf-form4_151787287602417.xml · nonDerivative · entry 2 Lundberg Jan M · CIK 0001480120 · EVP,Science&Tech and Pres. LRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 198,126 Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 23:21 UTC |
Lundberg Jan MEVP,Science&Tech and Pres. LRL
|
Exercise / conversionCommon Stock | 36,252 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-18-000066 · wf-form4_151787287602417.xml · nonDerivative · entry 1 Lundberg Jan M · CIK 0001480120 · EVP,Science&Tech and Pres. LRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,295 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 23:24 UTC |
Mahony SusanSVP & Pres., Lilly Oncology
|
Exercise / conversionRestricted Stock Unit · Derivative | 21,326 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-18-000068 · wf-form4_151787307587534.xml · derivative · entry 6 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,326 shares Expires 2018-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 23:24 UTC |
Mahony SusanSVP & Pres., Lilly Oncology
|
Tax withholdingCommon Stock | 9,533 | $81.45 | $776,462.85 |
DisclosureSEC source: 0000059478-18-000068 · wf-form4_151787307587534.xml · nonDerivative · entry 2 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,817 Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 23:24 UTC |
Mahony SusanSVP & Pres., Lilly Oncology
|
Exercise / conversionCommon Stock | 21,326 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-18-000068 · wf-form4_151787307587534.xml · nonDerivative · entry 1 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,350 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 23:31 UTC |
Ricks David ADirector · President & CEO
|
Exercise / conversionRestricted Stock Unit · Derivative | 21,326 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-18-000072 · wf-form4_151787345344416.xml · derivative · entry 5 Ricks David A · CIK 0001538604 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,326 shares Expires 2018-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.